What is the 13F Pro Quality Score for ANIK?

13F Pro ranks Anika Therapeutics, Inc. (ANIK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANIK's current score at https://13fpro.ai/research/ANIK (free sign-up required for the full ranking).

Which hedge funds own the most ANIK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ANIK include BlackRock,, Caligan Partners, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ANIK as soon as new 13F filings post.

Where does 13F Pro source ANIK data?

All Anika Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Anika Therapeutics, Inc. files with the SEC under CIK 898437. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANIK in?

Anika Therapeutics, Inc. (ANIK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANIK research updated on 13F Pro?

ANIK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Anika Therapeutics, Inc.(ANIK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 898437 ANIK stock profile & AI dashboard →

13F Pro Quality Score

25.4/100

Rank #2,548 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

33.2/100

Profitability

19.3/100

Balance Sheet

19.0/100

Earnings Quality

30.0/100

Free Cash Flow

23.3/100

Institutional Flow

66.7/100

Revenue Scale

18.5/100

Dilution Risk

18.3/100

ANIK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Anika Therapeutics, Inc. (ANIK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIK at 25.4/100 on a 32-signal composite quality model, placing it at rank #2,548 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (18.5) and balance sheet strength (19.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Anika Therapeutics, Inc. reports quarterly revenue of $29.6M, net income of $-5.1M, free cash flow of $-6.3M. Top institutional holders of ANIK by reported 13-F value include BlackRock,, Caligan Partners, MORGAN STANLEY, based on the most recent SEC filings. ANIK trades on the Nasdaq exchange and files with the SEC under CIK 898437. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anika Therapeutics, Inc. directly from SEC EDGAR. Anika Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 41 since 2021, currently 25.4 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Anika Therapeutics, Inc.

Quirks, history, and lore behind ANIK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty healthcare company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of roughly $160 million, with a focused portfolio that keeps it squarely in niche medical markets rather than blockbuster-drug territory.
3
The History
Founded in the 1990s, the company built its early business around hyaluronic acid — the same stuff your knees wish they had more of — and has been refining that chemistry ever since.
4
The Secret
Its core technology is naturally derived, biocompatible polymers injected directly into joints to relieve osteoarthritis pain — no surgery required, just a very targeted syringe.
5
The Lore
The company has steadily expanded beyond joints into dermal fillers and surgical anti-adhesion products, betting that one versatile molecule can do a lot of the body's dirty work.
6
The Giveaway
Its flagship viscosupplementation injections go straight into arthritic knees, its ticker rhymes with a body part, and the company name is a nod to a very scientific-sounding first name — ANIKa.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$29.6M

Net Income

Q1 2026

$-5.1M

Free Cash Flow

Q1 2026

$-6.3M

ROIC

Q1 2026

-4.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-5.9% YoY

$112.8MFY 2025

FY21 $147.8MFY23 $120.8MFY24 $119.9MFY25 $112.8M

Net Income

+80.4% YoY

$-11.0MFY 2025

FY21 $4.1MFY23 $-83.0MFY24 $-56.0MFY25 $-11.0M

Operating Income

-116.6% YoY

$-11.1MFY 2025

FY21 $2.6MFY23 $844.0KFY24 $-5.1MFY25 $-11.1M

EPS (Diluted)

+80.2% YoY

$-0.76FY 2025

FY21 $0.28FY23 $-5.64FY24 $-3.83FY25 $-0.76

Total Assets

-6.2% YoY

$190.3MFY 2025

FY21 $347.5MFY23 $270.6MFY24 $202.7MFY25 $190.3M

Op. Cash Flow

+107.1% YoY

$11.2MFY 2025

FY21 $8.4MFY23 $-1.8MFY24 $5.4MFY25 $11.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$112.8M -5.9%	$119.9M -0.7%	$120.8M -18.3%	$147.8M +13.3%	$130.5M +23.6%	$105.6M
Net Income	$-11.0M +80.4%	$-56.0M +32.5%	$-83.0M -2107.7%	$4.1M +117.2%	$-24.0M -228.1%	$18.7M
Operating Income	$-11.1M -116.6%	$-5.1M -704.4%	$844.0K -67.7%	$2.6M +109.2%	$-28.3M -230.2%	$21.7M
EPS (Diluted)	$-0.76 +80.2%	$-3.83 +32.1%	$-5.64 -2114.3%	$0.28 +116.6%	$-1.69 -233.1%	$1.27
Total Assets	$190.3M -6.2%	$202.7M -25.1%	$270.6M -22.1%	$347.5M -4.9%	$365.6M +31.0%	$279.0M
Operating Cash Flow	$11.2M +107.1%	$5.4M +402.2%	$-1.8M -121.3%	$8.4M -35.7%	$13.1M -62.6%	$34.9M

Get alerted when ANIK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Anika Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANIK

BlackRock, Inc.
$23.1M1,594,893 sh
Caligan Partners LP
$20.8M1,435,130 sh
MORGAN STANLEY
$12.6M872,066 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.8M605,777 sh
BOOTHBAY FUND MANAGEMENT, LLC
$7.7M529,503 sh
RENAISSANCE TECHNOLOGIES LLC
$7.3M502,217 sh
DIMENSIONAL FUND ADVISORS LP
$6.7M458,847 sh
CAPITAL MANAGEMENT CORP /VA
$6.5M447,721 sh
DEUTSCHE BANK AG\
$5.1M353,174 sh
STATE STREET CORP
$5.0M346,092 sh

Fund	Value	Shares
BlackRock, Inc.	$23.1M	1,594,893
Caligan Partners LP	$20.8M	1,435,130
MORGAN STANLEY	$12.6M	872,066
VANGUARD CAPITAL MANAGEMENT LLC	$8.8M	605,777
BOOTHBAY FUND MANAGEMENT, LLC	$7.7M	529,503
RENAISSANCE TECHNOLOGIES LLC	$7.3M	502,217
DIMENSIONAL FUND ADVISORS LP	$6.7M	458,847
CAPITAL MANAGEMENT CORP /VA	$6.5M	447,721
DEUTSCHE BANK AG\	$5.1M	353,174
STATE STREET CORP	$5.0M	346,092

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANIK on your watchlist

Track score changes the day Anika Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANIK a good stock to buy?

13F Pro's AI-powered analysis of Anika Therapeutics, Inc. (ANIK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIK are available on the ANIK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANIK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anika Therapeutics, Inc.'s investment landscape.